The UK and US have established a key trade agreement that will ensure zero levies on British pharmaceutical products going into the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to increase funding on drugs through the public health system. This move secures that duties on these key goods will remain at nothing for a period of 36 months.
This agreement comes after recent threats to dramatically increase import taxes on patented pharmaceutical imports, with potential rates mentioned as high as 100%.
"This arrangement with the United Kingdom reinforces the worldwide climate for innovative medicines and introduces much-needed fairness to American-British pharmaceutical trade," an announcement noted.
Commercial Importance
Drugs represent one of the UK's most significant goods shipped to the America, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Statistics show that in the 12 months to the end of September, the UK shipped drugs totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of all goods exports in that period.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement includes several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments were more than 20%.
Broader Context
The pact takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
These tensions were heightened by arguments that American customers were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its overall budget over the past decade.
